≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Other and unspecified cicatricial alopecia

DOID EFO Endpoint Browser PheWeb

L12_HAIRLOSS_SCARNAS

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

2 out of 7 registries used, show all original rules.

106

4. Check minimum number of events

None

106

5. Include endpoints

None

106

6. Filter based on genotype QC (FinnGen only)

105

Control definitions (FinnGen only)

Control exclude
L12_DISORDSKINAPPENDIX

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 559 452 105
Only index persons 544 440 104
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.00
Only index persons 0.01 0.02 0.00
Median age at first event (years)
Whole population 53.97 58.53 34.66
Only index persons 54.40 58.89 35.38

-FinnGen-

Key figures

All Female Male
Number of individuals 105 96 9
Unadjusted period prevalence (%) 0.03 0.03 0.00
Median age at first event (years) 61.51 62.27 53.44

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
106
Matched controls
1060
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L66.9
ICD-10 Finland
Cicatricial alopecia, unspecified
+∞
86.7
71
*
L66.8
ICD-10 Finland
Other cicatricial alopecia
+∞
52.5
46
*
D07AD01
ATC
clobetasol; topical
15.9
47.7
71
120
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
13.1
33.8
40
47
D07AC01
ATC
betamethasone; topical
7.2
21.3
76
276
P01BA02
ATC
hydroxychloroquine; oral
7.7
21.0
38
72
L66.1
ICD-10 Finland
Lichen planopilaris
+∞
18.2
17
*
L30.9
ICD-10 Finland
Dermatitis, unspecified
5.6
16.9
48
137
D07XC01
ATC
betamethasone; topical
6.2
13.8
28
58
L63.9
ICD-10 Finland
Alopecia areata, unspecified
134.0
11.7
12
*
D07AC13
ATC
mometasone; topical
3.6
9.4
50
212
J01AA04
ATC
lymecycline; systemic
4.7
9.0
24
62
XQ845
NOMESCO Finland
Dermatoscopy
15.1
7.1
11
8
L65.9
ICD-10 Finland
Nonscarring hair loss, unspecified
42.9
6.9
8
*
XQ848
NOMESCO Finland
Dermatological photography
11.1
6.7
12
12
D06BX01
ATC
metronidazole; topical
3.8
6.4
22
68
L71.8
ICD-10 Finland
Other rosacea
28.5
6.3
8
*
L66.2
ICD-10 Finland
Folliculitis decalvans
+∞
6.3
6
*
E000001, ,
ATC
3.0
6.0
34
144

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
1.6e+00
2.6e+00
2.5e+00
1.0e+50
4.8e+00
4.6e+00
3.1e+00
cases:27.36%
controls:7.01%
cases:28.30%
controls:2.75%
cases:8.49%
controls:0.76%
cases:95.28%
controls:0.00%
cases:37.14%
controls:0.48%
cases:73.00%
controls:2.61%
cases:60.76%
controls:6.81%
29
74
77
982
30
29
76
1027
9
8
97
1048
101
0
5
1056
39
5
66
1045
73
26
27
970
48
53
31
725
clobetasol
D07AD01 [21602141]
1.8e+00
2.9e+00
—
1.0e+50
1.0e+50
3.4e+00
3.0e+00
cases:13.21%
controls:2.56%
cases:22.64%
controls:1.52%
—
—
cases:11.32%
controls:0.00%
cases:20.00%
controls:0.00%
cases:32.00%
controls:1.51%
cases:39.24%
controls:3.08%
14
27
92
1029
24
16
82
1040
—
12
0
94
1056
21
0
84
1050
32
15
68
981
31
24
48
754
betamethasone
S03BA03 [21605203]
2.2e+00
3.4e+00
—
—
1.0e+50
3.0e+00
2.4e+00
cases:16.04%
controls:2.08%
cases:15.09%
controls:0.57%
—
—
—
—
cases:9.52%
controls:0.00%
cases:13.00%
controls:0.70%
cases:17.72%
controls:1.93%
17
22
89
1034
16
6
90
1050
—
—
10
0
95
1050
13
7
87
989
14
15
65
763
hydroxychloroquine; oral
P01BA02 [21604889]
1.0e+00
1.6e+00
2.3e+00
—
—
2.9e+00
2.4e+00
cases:6.60%
controls:2.46%
cases:8.49%
controls:1.80%
cases:5.66%
controls:0.57%
—
—
—
—
cases:28.00%
controls:2.01%
cases:21.52%
controls:2.44%
7
26
99
1030
9
19
97
1037
6
6
100
1050
—
—
28
20
72
976
17
19
62
759
Outpatient Visit
OP [9202]
1.3e-01
6.6e-01
9.8e-01
5.1e+00
1.6e+00
1.1e+00
1.1e+00
cases:80.19%
controls:78.13%
cases:69.81%
controls:54.36%
cases:19.81%
controls:8.52%
cases:54.72%
controls:0.76%
cases:36.19%
controls:10.67%
cases:78.00%
controls:54.52%
cases:93.67%
controls:83.03%
85
825
21
231
74
574
32
482
21
90
85
966
58
8
48
1048
38
112
67
938
78
543
22
453
74
646
5
132
betamethasone
A07EA04 [21600656]
1.4e+00
2.2e+00
—
—
—
1.6e+00
1.9e+00
cases:25.47%
controls:7.48%
cases:19.81%
controls:2.75%
—
—
—
—
—
—
cases:17.00%
controls:3.82%
cases:35.44%
controls:7.46%
27
79
79
977
21
29
85
1027
—
—
—
17
38
83
958
28
58
51
720
betamethasone
C05AA05 [21601610]
1.4e+00
2.2e+00
—
—
—
1.6e+00
1.9e+00
cases:25.47%
controls:7.48%
cases:19.81%
controls:2.75%
—
—
—
—
—
—
cases:17.00%
controls:3.82%
cases:35.44%
controls:7.46%
27
79
79
977
21
29
85
1027
—
—
—
17
38
83
958
28
58
51
720
betamethasone
S02BA07 [21605169]
1.4e+00
2.2e+00
—
—
—
1.6e+00
1.9e+00
cases:25.47%
controls:7.48%
cases:19.81%
controls:2.75%
—
—
—
—
—
—
cases:17.00%
controls:3.82%
cases:35.44%
controls:7.46%
27
79
79
977
21
29
85
1027
—
—
—
17
38
83
958
28
58
51
720
betamethasone
D07AC01 [21602120]
1.4e+00
2.2e+00
—
—
—
1.6e+00
1.9e+00
cases:25.47%
controls:7.48%
cases:19.81%
controls:2.75%
—
—
—
—
—
—
cases:17.00%
controls:3.82%
cases:35.44%
controls:7.46%
27
79
79
977
21
29
85
1027
—
—
—
17
38
83
958
28
58
51
720
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
—
2.5e+00
—
1.0e+50
—
2.4e+00
1.8e+00
—
—
cases:7.55%
controls:0.66%
—
—
cases:5.66%
controls:0.00%
—
—
cases:7.00%
controls:0.70%
cases:12.66%
controls:2.31%
—
8
7
98
1049
—
6
0
100
1056
—
7
7
93
989
10
18
69
760
Pharmacy visit
OMOP4822462 [581458]
1.4e+00
2.4e+00
8.1e-01
2.7e+00
7.5e-01
1.7e+00
1.0e+50
cases:99.06%
controls:96.31%
cases:99.06%
controls:90.34%
cases:71.70%
controls:52.94%
cases:31.13%
controls:3.03%
cases:70.48%
controls:53.05%
cases:98.00%
controls:89.96%
cases:100.00%
controls:97.56%
105
1017
1
39
105
954
1
102
76
559
30
497
33
32
73
1024
74
557
31
493
98
896
2
100
79
759
0
19
other preparations, combinations; ointment
C05AX03 [21601631]
1.9e+00
—
—
—
—
2.2e+00
1.6e+00
cases:10.38%
controls:1.70%
—
—
—
—
—
—
—
—
cases:7.00%
controls:0.80%
cases:11.39%
controls:2.57%
11
18
95
1038
—
—
—
—
7
8
93
988
9
20
70
758
mometasone
D07AC13 [21602132]
1.1e+00
2.1e+00
—
—
—
1.9e+00
1.4e+00
cases:12.26%
controls:4.64%
cases:9.43%
controls:1.23%
—
—
—
—
—
—
cases:7.00%
controls:1.10%
cases:12.66%
controls:3.34%
13
49
93
1007
10
13
96
1043
—
—
—
7
11
93
985
10
26
69
752
Supplier / Service Provider
OMOP5117446 [33004]
-7.6e-01
—
—
—
—
2.7e+00
2.6e+00
cases:15.09%
controls:27.46%
—
—
—
—
—
—
—
—
cases:8.00%
controls:0.60%
cases:20.25%
controls:1.93%
16
290
90
766
—
—
—
—
8
6
92
990
16
15
63
763
Dermatitis, unspecified
L30.9 [45572271]
1.3e+00
3.0e+00
—
—
—
1.8e+00
1.1e+00
cases:8.49%
controls:2.37%
cases:16.98%
controls:1.04%
—
—
—
—
—
—
cases:7.00%
controls:1.20%
cases:12.66%
controls:4.50%
9
25
97
1031
18
11
88
1045
—
—
—
7
12
93
984
10
35
69
743
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
1.3e+00
2.0e+00
—
—
—
1.7e+00
1.3e+00
cases:13.21%
controls:3.98%
cases:8.49%
controls:1.23%
—
—
—
—
—
—
cases:7.00%
controls:1.31%
cases:15.19%
controls:4.63%
14
42
92
1014
9
13
97
1043
—
—
—
7
13
93
983
12
36
67
742
Actinic keratosis
L57.0 [45591640]
2.1e+00
—
—
1.0e+50
—
—
2.0e+00
cases:9.43%
controls:1.23%
—
—
—
—
cases:5.66%
controls:0.00%
—
—
—
—
cases:10.13%
controls:1.54%
10
13
96
1043
—
—
6
0
100
1056
—
—
8
12
71
766
hydrocortisone buteprate
D07AB11 [21602115]
9.8e-01
1.7e+00
—
—
—
9.6e-01
1.0e+00
cases:19.81%
controls:8.52%
cases:12.26%
controls:2.37%
—
—
—
—
—
—
cases:8.00%
controls:3.21%
cases:22.78%
controls:9.38%
21
90
85
966
13
25
93
1031
—
—
—
8
32
92
964
18
73
61
705
hydrocortisone
D07AA02 [21602102]
9.8e-01
1.7e+00
—
—
—
9.6e-01
1.0e+00
cases:19.81%
controls:8.52%
cases:12.26%
controls:2.37%
—
—
—
—
—
—
cases:8.00%
controls:3.21%
cases:22.78%
controls:9.38%
21
90
85
966
13
25
93
1031
—
—
—
8
32
92
964
18
73
61
705
hydrocortisone aceponate
D07AC16 [21602135]
9.8e-01
1.7e+00
—
—
—
9.6e-01
1.0e+00
cases:19.81%
controls:8.52%
cases:12.26%
controls:2.37%
—
—
—
—
—
—
cases:8.00%
controls:3.21%
cases:22.78%
controls:9.38%
21
90
85
966
13
25
93
1031
—
—
—
8
32
92
964
18
73
61
705
hydrocortisone butyrate
D07AB02 [21602106]
9.8e-01
1.7e+00
—
—
—
9.6e-01
1.0e+00
cases:19.81%
controls:8.52%
cases:12.26%
controls:2.37%
—
—
—
—
—
—
cases:8.00%
controls:3.21%
cases:22.78%
controls:9.38%
21
90
85
966
13
25
93
1031
—
—
—
8
32
92
964
18
73
61
705
hydrocortisone
A07EA02 [21600654]
9.6e-01
1.7e+00
—
—
—
9.6e-01
1.0e+00
cases:19.81%
controls:8.62%
cases:12.26%
controls:2.37%
—
—
—
—
—
—
cases:8.00%
controls:3.21%
cases:22.78%
controls:9.38%
21
91
85
965
13
25
93
1031
—
—
—
8
32
92
964
18
73
61
705
hydrocortisone
C05AA01 [21601608]
9.6e-01
1.7e+00
—
—
—
9.6e-01
1.0e+00
cases:19.81%
controls:8.62%
cases:12.26%
controls:2.37%
—
—
—
—
—
—
cases:8.00%
controls:3.21%
cases:22.78%
controls:9.38%
21
91
85
965
13
25
93
1031
—
—
—
8
32
92
964
18
73
61
705
Case Management Agency
251B00000X [38004193]
2.0e-02
3.7e-02
4.3e-02
3.3e+00
4.9e-01
2.4e-01
2.1e-01
cases:75.47%
controls:75.09%
cases:70.75%
controls:69.98%
cases:31.13%
controls:30.21%
cases:40.57%
controls:2.37%
cases:40.95%
controls:29.90%
cases:75.00%
controls:70.28%
cases:87.34%
controls:84.83%
80
793
26
263
75
739
31
317
33
319
73
737
43
25
63
1031
43
314
62
736
75
700
25
296
69
660
10
118
Laboratory Visit
OMOP4822461 [32036]
1.3e-01
3.4e-01
6.1e-01
3.2e+00
5.7e-01
5.5e-01
1.6e-01
cases:58.49%
controls:55.21%
cases:59.43%
controls:50.95%
cases:26.42%
controls:16.29%
cases:28.30%
controls:1.61%
cases:24.76%
controls:15.71%
cases:66.00%
controls:52.81%
cases:72.15%
controls:68.89%
62
583
44
473
63
538
43
518
28
172
78
884
30
17
76
1039
26
165
79
885
66
526
34
470
57
536
22
242
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
2.9e-01
2.6e-01
—
—
—
1.5e+00
1.5e+00
cases:6.60%
controls:5.02%
cases:4.72%
controls:3.69%
—
—
—
—
—
—
cases:13.00%
controls:3.31%
cases:25.32%
controls:7.33%
7
53
99
1003
5
39
101
1017
—
—
—
13
33
87
963
20
57
59
721
Skin Pathology biopsy report
65754-4 [40768443]
—
2.7e+00
—
1.0e+50
—
—
—
—
—
cases:6.60%
controls:0.47%
—
—
cases:16.98%
controls:0.00%
—
—
—
—
—
—
—
7
5
99
1051
—
18
0
88
1056
—
—
—
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
-1.8e-02
6.5e-01
—
—
—
1.5e+00
1.2e+00
cases:7.55%
controls:7.67%
cases:5.66%
controls:3.03%
—
—
—
—
—
—
cases:10.00%
controls:2.51%
cases:18.99%
controls:6.68%
8
81
98
975
6
32
100
1024
—
—
—
10
25
90
971
15
52
64
726
combinations of corticosteroids
D07XB30 [21602188]
1.0e+00
1.6e+00
2.3e+00
—
—
1.0e+00
7.9e-01
cases:27.36%
controls:11.84%
cases:16.04%
controls:3.88%
cases:4.72%
controls:0.47%
—
—
—
—
cases:11.00%
controls:4.22%
cases:25.32%
controls:13.37%
29
125
77
931
17
41
89
1015
5
5
101
1051
—
—
11
42
89
954
20
104
59
674
combinations of corticosteroids
D07AB30 [21602118]
1.0e+00
1.6e+00
2.3e+00
—
—
1.0e+00
7.9e-01
cases:27.36%
controls:11.84%
cases:16.04%
controls:3.88%
cases:4.72%
controls:0.47%
—
—
—
—
cases:11.00%
controls:4.22%
cases:25.32%
controls:13.37%
29
125
77
931
17
41
89
1015
5
5
101
1051
—
—
11
42
89
954
20
104
59
674
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4.2e-01
1.0e+00
1.5e+00
—
1.4e+00
6.5e-01
6.8e-01
cases:34.91%
controls:26.04%
cases:27.36%
controls:11.93%
cases:10.38%
controls:2.46%
—
—
cases:6.67%
controls:1.81%
cases:21.00%
controls:12.15%
cases:46.84%
controls:30.85%
37
275
69
781
29
126
77
930
11
26
95
1030
—
7
19
98
1031
21
121
79
875
37
240
42
538
lymecycline; oral, parenteral
J01AA04 [21602802]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.86%
controls:0.77%
—
—
—
—
—
—
7
6
72
772
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
8.0e-02
2.6e-01
8.7e-01
2.5e+00
5.8e-01
3.9e-01
5.1e-01
cases:49.06%
controls:47.06%
cases:42.45%
controls:36.17%
cases:16.98%
controls:7.86%
cases:7.55%
controls:0.66%
cases:13.33%
controls:7.90%
cases:47.00%
controls:37.45%
cases:72.15%
controls:60.80%
52
497
54
559
45
382
61
674
18
83
88
973
8
7
98
1049
14
83
91
967
47
373
53
623
57
473
22
305
Biopsy of skin and subcutaneous tissue
TQX10 [2001310152]
1.8e+00
—
—
1.0e+50
—
—
2.4e+00
cases:5.66%
controls:0.95%
—
—
—
—
cases:16.04%
controls:0.00%
—
—
—
—
cases:8.86%
controls:0.90%
6
10
100
1046
—
—
17
0
89
1056
—
—
7
7
72
771
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.7e-01
3.8e-01
7.3e-01
2.4e+00
2.5e-01
5.4e-01
3.2e-01
cases:54.72%
controls:50.57%
cases:50.00%
controls:40.72%
cases:18.87%
controls:10.04%
cases:6.60%
controls:0.66%
cases:12.38%
controls:9.90%
cases:56.00%
controls:42.57%
cases:70.89%
controls:63.88%
58
534
48
522
53
430
53
626
20
106
86
950
7
7
99
1049
13
104
92
946
56
424
44
572
56
497
23
281
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.6e-01
3.7e-01
7.3e-01
2.4e+00
2.5e-01
5.4e-01
3.1e-01
cases:54.72%
controls:50.66%
cases:50.00%
controls:40.91%
cases:18.87%
controls:10.04%
cases:6.60%
controls:0.66%
cases:12.38%
controls:9.90%
cases:56.00%
controls:42.57%
cases:70.89%
controls:64.14%
58
535
48
521
53
432
53
624
20
106
86
950
7
7
99
1049
13
104
92
946
56
424
44
572
56
499
23
279
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.7e-01
3.7e-01
7.3e-01
2.4e+00
2.5e-01
5.4e-01
3.1e-01
cases:54.72%
controls:50.57%
cases:50.00%
controls:40.81%
cases:18.87%
controls:10.04%
cases:6.60%
controls:0.66%
cases:12.38%
controls:9.90%
cases:56.00%
controls:42.57%
cases:70.89%
controls:64.01%
58
534
48
522
53
431
53
625
20
106
86
950
7
7
99
1049
13
104
92
946
56
424
44
572
56
498
23
280
MCH [Entitic mass]
28539-5 [3035941]
1.7e-01
3.7e-01
7.3e-01
2.4e+00
2.5e-01
5.4e-01
3.1e-01
cases:54.72%
controls:50.57%
cases:50.00%
controls:40.81%
cases:18.87%
controls:10.04%
cases:6.60%
controls:0.66%
cases:12.38%
controls:9.90%
cases:56.00%
controls:42.47%
cases:70.89%
controls:64.01%
58
534
48
522
53
431
53
625
20
106
86
950
7
7
99
1049
13
104
92
946
56
423
44
573
56
498
23
280
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.7e-01
3.8e-01
7.4e-01
2.4e+00
2.5e-01
5.4e-01
3.1e-01
cases:54.72%
controls:50.47%
cases:50.00%
controls:40.72%
cases:18.87%
controls:9.94%
cases:6.60%
controls:0.66%
cases:12.38%
controls:9.90%
cases:56.00%
controls:42.47%
cases:70.89%
controls:64.01%
58
533
48
523
53
430
53
626
20
105
86
951
7
7
99
1049
13
104
92
946
56
423
44
573
56
498
23
280
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.7e-01
4.4e-01
7.2e-01
2.4e+00
2.4e-01
5.4e-01
3.1e-01
cases:54.72%
controls:50.47%
cases:51.89%
controls:41.00%
cases:18.87%
controls:10.13%
cases:6.60%
controls:0.66%
cases:12.38%
controls:10.00%
cases:56.00%
controls:42.57%
cases:70.89%
controls:64.01%
58
533
48
523
55
433
51
623
20
107
86
949
7
7
99
1049
13
105
92
945
56
424
44
572
56
498
23
280
Platelets [#/volume] in Blood
26515-7 [3007461]
1.7e-01
3.7e-01
7.3e-01
2.4e+00
2.5e-01
5.4e-01
3.1e-01
cases:54.72%
controls:50.47%
cases:50.00%
controls:40.81%
cases:18.87%
controls:10.04%
cases:6.60%
controls:0.66%
cases:12.38%
controls:9.90%
cases:56.00%
controls:42.57%
cases:70.89%
controls:64.01%
58
533
48
523
53
431
53
625
20
106
86
950
7
7
99
1049
13
104
92
946
56
424
44
572
56
498
23
280
Extractable nuclear Ab [Units/volume] in Serum
30342-0 [3015171]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.86%
controls:1.03%
—
—
—
—
—
—
7
8
72
770
Microorganisms panel - Urine sediment
58435-9 [40761536]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.39%
controls:1.41%
—
—
—
—
—
—
9
11
70
767
pimecrolimus
D11AH02 [21602339]
2.3e+00
—
—
—
—
—
2.1e+00
cases:4.72%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
cases:8.86%
controls:1.16%
5
5
101
1051
—
—
—
—
—
7
9
72
769
Monocytes [#/volume] in Blood
26484-6 [3001604]
2.1e-01
3.2e-01
1.1e+00
1.0e+50
1.3e+00
1.2e+00
9.1e-01
cases:17.92%
controls:15.06%
cases:13.21%
controls:9.94%
cases:7.55%
controls:2.75%
cases:4.72%
controls:0.00%
cases:6.67%
controls:2.00%
cases:26.00%
controls:9.64%
cases:32.91%
controls:16.45%
19
159
87
897
14
105
92
951
8
29
98
1027
5
0
101
1056
7
21
98
1029
26
96
74
900
26
128
53
650
Basophils [#/volume] in Blood
26444-0 [3006315]
2.0e-01
3.1e-01
1.1e+00
1.0e+50
1.2e+00
1.2e+00
9.1e-01
cases:17.92%
controls:15.15%
cases:13.21%
controls:10.04%
cases:7.55%
controls:2.75%
cases:4.72%
controls:0.00%
cases:6.67%
controls:2.10%
cases:26.00%
controls:9.64%
cases:32.91%
controls:16.45%
19
160
87
896
14
106
92
950
8
29
98
1027
5
0
101
1056
7
22
98
1028
26
96
74
900
26
128
53
650
Fungus identified in Specimen by Culture
580-1 [3000494]
8.2e-01
2.1e+00
—
—
—
—
—
cases:6.60%
controls:3.03%
cases:6.60%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
7
32
99
1024
7
9
99
1047
—
—
—
—
—
Eosinophils [#/volume] in Blood
26449-9 [3013115]
2.1e-01
3.6e-01
1.0e+00
1.0e+50
1.0e+00
1.1e+00
8.8e-01
cases:18.87%
controls:15.91%
cases:14.15%
controls:10.32%
cases:7.55%
controls:2.84%
cases:4.72%
controls:0.00%
cases:6.67%
controls:2.48%
cases:26.00%
controls:10.04%
cases:32.91%
controls:16.97%
20
168
86
888
15
109
91
947
8
30
98
1026
5
0
101
1056
7
26
98
1024
26
100
74
896
26
132
53
646
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
1.1e-01
2.8e-01
8.8e-01
1.0e+50
1.3e+00
1.1e+00
8.9e-01
cases:16.98%
controls:15.44%
cases:13.21%
controls:10.32%
cases:6.60%
controls:2.84%
cases:4.72%
controls:0.00%
cases:6.67%
controls:2.00%
cases:26.00%
controls:10.34%
cases:32.91%
controls:16.71%
18
163
88
893
14
109
92
947
7
30
99
1026
5
0
101
1056
7
21
98
1029
26
103
74
893
26
130
53
648
Dry eye syndrome
H04.10 [2000502254]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.39%
controls:2.06%
—
—
—
—
—
—
9
16
70
762
methotrexate; oral, parenteral
L04AX03 [21603929]
8.2e-01
1.2e+00
—
—
—
1.3e+00
1.8e+00
cases:6.60%
controls:3.03%
cases:6.60%
controls:2.08%
—
—
—
—
—
—
cases:8.00%
controls:2.41%
cases:12.66%
controls:2.31%
7
32
99
1024
7
22
99
1034
—
—
—
8
24
92
972
10
18
69
760
methotrexate
L01BA01 [21601423]
8.2e-01
1.2e+00
—
—
—
1.3e+00
1.8e+00
cases:6.60%
controls:3.03%
cases:6.60%
controls:2.08%
—
—
—
—
—
—
cases:8.00%
controls:2.41%
cases:12.66%
controls:2.31%
7
32
99
1024
7
22
99
1034
—
—
—
8
24
92
972
10
18
69
760
Bacteria identified in Isolate by Culture
43409-2 [3042936]
2.6e-01
—
—
—
—
—
1.7e+00
cases:4.72%
controls:3.69%
—
—
—
—
—
—
—
—
—
—
cases:10.13%
controls:2.06%
5
39
101
1017
—
—
—
—
—
8
16
71
762
Normoblasts [#/volume] in Blood
715-3 [3021589]
2.8e-01
2.0e-01
1.6e+00
—
—
4.3e-01
3.2e-01
cases:16.98%
controls:13.45%
cases:11.32%
controls:9.47%
cases:8.49%
controls:1.80%
—
—
—
—
cases:15.00%
controls:10.34%
cases:22.78%
controls:17.61%
18
142
88
914
12
100
94
956
9
19
97
1037
—
—
15
103
85
893
18
137
61
641
desloratadine; oral
R06AX27 [21603526]
7.0e-01
1.2e+00
—
—
—
1.3e+00
9.0e-01
cases:13.21%
controls:7.01%
cases:9.43%
controls:2.94%
—
—
—
—
—
—
cases:12.00%
controls:3.41%
cases:13.92%
controls:6.17%
14
74
92
982
10
31
96
1025
—
—
—
12
34
88
962
11
48
68
730
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
3.5e-01
9.7e-01
—
—
—
7.4e-01
1.3e+00
cases:10.38%
controls:7.58%
cases:8.49%
controls:3.41%
—
—
—
—
—
—
cases:10.00%
controls:5.02%
cases:29.11%
controls:9.77%
11
80
95
976
9
36
97
1020
—
—
—
10
50
90
946
23
76
56
702
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
2.1e-01
5.8e-01
—
—
—
4.5e-01
1.3e+00
cases:14.15%
controls:11.84%
cases:9.43%
controls:5.49%
—
—
—
—
—
—
cases:10.00%
controls:6.63%
cases:35.44%
controls:13.50%
15
125
91
931
10
58
96
998
—
—
—
10
66
90
930
28
105
51
673
Specific gravity of Urine by Refractometry
5810-7 [3019150]
-1.1e-01
6.1e-01
—
—
—
4.9e-01
1.1e+00
cases:6.60%
controls:7.29%
cases:6.60%
controls:3.69%
—
—
—
—
—
—
cases:7.00%
controls:4.42%
cases:21.52%
controls:8.61%
7
77
99
979
7
39
99
1017
—
—
—
7
44
93
952
17
67
62
711
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
1.1e-01
4.0e-01
7.3e-01
—
8.4e-01
9.7e-01
6.1e-01
cases:20.75%
controls:19.03%
cases:16.04%
controls:11.36%
cases:7.55%
controls:3.79%
—
—
cases:7.62%
controls:3.43%
cases:26.00%
controls:11.75%
cases:31.65%
controls:20.05%
22
201
84
855
17
120
89
936
8
40
98
1016
—
8
36
97
1014
26
117
74
879
25
156
54
622
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
2.6e-01
4.0e-01
—
—
—
4.3e-01
9.7e-01
cases:16.98%
controls:13.64%
cases:11.32%
controls:7.86%
—
—
—
—
—
—
cases:13.00%
controls:8.84%
cases:37.97%
controls:18.89%
18
144
88
912
12
83
94
973
—
—
—
13
88
87
908
30
147
49
631
Cardiology
6 [38004451]
-2.3e-02
2.5e-01
—
—
—
7.6e-01
9.6e-01
cases:11.32%
controls:11.55%
cases:6.60%
controls:5.21%
—
—
—
—
—
—
cases:9.00%
controls:4.42%
cases:25.32%
controls:11.44%
12
122
94
934
7
55
99
1001
—
—
—
9
44
91
952
20
89
59
689
cefalexin; oral
J01DB01 [21602870]
6.3e-01
9.6e-01
-1.0e+50
—
-1.0e+50
-9.8e-02
3.8e-01
cases:46.23%
controls:31.34%
cases:21.70%
controls:9.56%
cases:0.00%
controls:1.89%
—
—
cases:0.00%
controls:1.24%
cases:9.00%
controls:9.84%
cases:30.38%
controls:23.01%
49
331
57
725
23
101
83
955
0
20
106
1036
—
0
13
105
1037
9
98
91
898
24
179
55
599
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
2.7e-01
9.6e-01
—
—
—
3.4e-01
6.1e-01
cases:33.96%
controls:28.22%
cases:33.96%
controls:16.48%
—
—
—
—
—
—
cases:21.00%
controls:15.96%
cases:48.10%
controls:33.55%
36
298
70
758
36
174
70
882
—
—
—
21
159
79
837
38
261
41
517
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
2.0e-01
3.8e-01
—
—
—
4.2e-01
9.3e-01
cases:16.98%
controls:14.30%
cases:11.32%
controls:8.05%
—
—
—
—
—
—
cases:13.00%
controls:8.94%
cases:37.97%
controls:19.41%
18
151
88
905
12
85
94
971
—
—
—
13
89
87
907
30
151
49
627
pH of Urine
2756-5 [3015736]
4.4e-01
2.2e-01
—
—
—
2.8e-01
9.2e-01
cases:16.04%
controls:10.98%
cases:7.55%
controls:6.16%
—
—
—
—
—
—
cases:9.00%
controls:6.93%
cases:29.11%
controls:14.01%
17
116
89
940
8
65
98
991
—
—
—
9
69
91
927
23
109
56
669
Internal Medicine
11 [38004456]
2.0e-01
5.1e-01
—
—
—
5.8e-01
9.2e-01
cases:22.64%
controls:19.32%
cases:12.26%
controls:7.77%
—
—
—
—
—
—
cases:13.00%
controls:7.73%
cases:31.65%
controls:15.55%
24
204
82
852
13
82
93
974
—
—
—
13
77
87
919
25
121
54
657
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
2.3e-01
4.0e-01
—
—
—
4.1e-01
9.2e-01
cases:16.98%
controls:14.02%
cases:11.32%
controls:7.86%
—
—
—
—
—
—
cases:13.00%
controls:9.04%
cases:37.97%
controls:19.67%
18
148
88
908
12
83
94
973
—
—
—
13
90
87
906
30
153
49
625
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
1.5e-01
8.3e-01
3.4e-01
—
8.0e-01
1.1e-01
3.5e-01
cases:40.57%
controls:36.93%
cases:39.62%
controls:22.25%
cases:4.72%
controls:3.41%
—
—
cases:4.76%
controls:2.19%
cases:26.00%
controls:24.00%
cases:53.16%
controls:44.47%
43
390
63
666
42
235
64
821
5
36
101
1020
—
5
23
100
1027
26
239
74
757
42
346
37
432
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1.4e-01
4.5e-01
8.6e-01
—
3.4e-01
7.1e-01
5.4e-01
cases:49.06%
controls:45.45%
cases:42.45%
controls:32.01%
cases:14.15%
controls:6.53%
—
—
cases:9.52%
controls:6.95%
cases:51.00%
controls:33.84%
cases:69.62%
controls:57.20%
52
480
54
576
45
338
61
718
15
69
91
987
—
10
73
95
977
51
337
49
659
55
445
24
333
lisinopril and diuretics
C09BA03 [21601805]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
cases:0.00%
controls:0.70%
cases:0.00%
controls:1.29%
—
0
7
106
1049
—
—
—
0
7
100
989
0
10
79
768
Supine thorax X-ray examination
GD1QA [2001303648]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.10%
cases:0.00%
controls:3.34%
—
—
—
—
—
0
11
100
985
0
26
79
752
Melaena
K92.1 [45533624]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
5
79
773
Stomach Pathology biopsy report
66114-0 [40768797]
—
—
—
—
—
—
4.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.33%
controls:4.24%
—
—
—
—
—
—
5
33
74
745
Hemoglobin [Mass/volume] in Capillary blood
30352-9 [3006184]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
0
8
106
1048
—
—
—
—
—
0
5
79
773
scopolamine; oral, parenteral
N05CM05 [21604666]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.33%
controls:1.16%
—
—
—
—
—
—
5
9
74
769
zoster, purified antigen
J07BK03 [1501889]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
8
79
770
Comprehensive monitoring of chronic illness
SPAT1250 [2001700351]
2.4e-01
4.9e-01
—
—
—
—
4.5e-01
cases:9.43%
controls:7.58%
cases:4.72%
controls:2.94%
—
—
—
—
—
—
—
—
cases:10.13%
controls:6.68%
10
80
96
976
5
31
101
1025
—
—
—
—
8
52
71
726
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
3.3e-01
-4.5e-02
—
—
-1.0e+50
—
3.4e-01
cases:12.26%
controls:9.09%
cases:4.72%
controls:4.92%
—
—
—
—
cases:0.00%
controls:0.95%
—
—
cases:15.19%
controls:11.31%
13
96
93
960
5
52
101
1004
—
—
0
10
105
1040
—
12
88
67
690
dexamethasone
S01CB01 [21603664]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
0
7
79
771
Participation in compiling a psychiatric treatment plan
ICZ03 [2001304119]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
106
1049
—
—
—
—
—
—
Sequelae of cerebral infarction
I69.3 [45533476]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
0
5
106
1051
—
—
—
0
5
100
991
—
Other psychiatric treatment contact
IGY99 [2001304323]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
—
Cardiac arrhythmia NOS
K80 [2002000607]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
0
7
106
1049
—
—
—
—
—
alprazolam; oral
N05BA12 [21604577]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.33%
cases:0.00%
controls:0.47%
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
0
14
106
1042
0
5
106
1051
—
—
—
0
7
100
989
—
ethinylestradiol; oral
G03CA01 [21602516]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
106
1050
—
—
—
—
—
—
metronidazole; vaginal
G01AF01 [21602392]
8.3e-01
—
—
—
—
—
1.5e+00
cases:5.66%
controls:2.56%
—
—
—
—
—
—
—
—
—
—
cases:6.33%
controls:1.54%
6
27
100
1029
—
—
—
—
—
5
12
74
766
Lesion of ulnar nerve
G56.2 [45595951]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
—
sildenafil; oral
G04BE03 [21602648]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
cases:0.00%
controls:0.70%
cases:0.00%
controls:1.16%
—
0
9
106
1047
—
—
—
0
7
100
989
0
9
79
769
Phakoemulsification with implantation of artificial lens in posterior chamber
CJE20 [2001301342]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
0
14
100
982
—
Infraclavicular plexus blockade
WX203 [2001310779]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
106
1049
—
—
—
—
—
—
Thyrotoxicosis, unspecified
E05.9 [45586131]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
106
1050
—
—
—
—
—
—
olaflur; oral
A01AA03 [21600007]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
—
Assessment of need for services (elderly/care support)
SPAT1217 [2001700318]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.93%
0
10
106
1046
—
—
—
—
—
0
15
79
763
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
-2.3e-01
—
-1.0e+50
—
—
4.2e-01
5.0e-01
cases:4.72%
controls:5.87%
—
—
cases:0.00%
controls:1.33%
—
—
—
—
cases:6.00%
controls:4.02%
cases:17.72%
controls:11.57%
5
62
101
994
—
0
14
106
1042
—
—
6
40
94
956
14
90
65
688
Ankylosing spondylitis
M45 [45591841]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
106
1050
—
—
—
—
—
—
Other iron deficiency anaemias
D50.8 [45571629]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
106
1047
—
—
—
—
—
—
hepatitis B, purified antigen
J07BC01 [21601338]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
106
1046
—
—
—
—
—
—
Written specialist consultation based on a referral from a dentist or a physician
WZC10 [2001310887]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
—
Medical examin/health eval partial
-31 [2002000102]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
106
1048
—
—
—
—
—
—
olanzapine; oral, parenteral
N05AH03 [21604543]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
0
6
100
990
—
Oxygen capacity [Volume Fraction] in Arterial blood
59275-8 [40762366]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
cases:0.00%
controls:1.29%
0
7
106
1049
—
—
—
—
0
5
100
991
0
10
79
768
Acute bronchitis
J20 [45581849]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
—
0
11
106
1045
—
—
—
—
—
Leukocytes [Presence] in Urine
33052-2 [3045414]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
106
1050
—
—
—
—
—
—
ABO and Rh group [Type] in Blood
882-1 [3003694]
-1.1e-01
—
—
—
—
—
5.2e-03
cases:5.66%
controls:6.25%
—
—
—
—
—
—
—
—
—
—
cases:6.33%
controls:6.30%
6
66
100
990
—
—
—
—
—
5
49
74
729
Blepharoconjunctivitis
H10.5 [45600848]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
—
Tinnitus
H93.1 [45543152]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
0
9
106
1047
—
—
—
—
0
6
100
990
—
empagliflozin; oral
A10BK03 [1123740]
—
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
cases:0.00%
controls:1.61%
—
—
—
—
0
5
106
1051
—
—
0
16
100
980
—
Basophils/Leukocytes in Blood
30180-4 [3022096]
2.9e-01
2.9e-01
9.5e-01
—
1.0e+00
6.5e-01
5.4e-01
cases:18.87%
controls:14.77%
cases:12.26%
controls:9.47%
cases:6.60%
controls:2.65%
—
—
cases:5.71%
controls:2.10%
cases:16.00%
controls:9.04%
cases:22.78%
controls:14.65%
20
156
86
900
13
100
93
956
7
28
99
1028
—
6
22
99
1028
16
90
84
906
18
114
61
664
Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood
19258-3 [3004529]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
0
7
100
989
—
Hand and fingers extensive X-ray examination
ND2BA [2001307610]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
5
79
773
Carboxyhemoglobin/Hemoglobin.total in Venous blood
2032-1 [3010517]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
0
7
100
989
—
Hypothyroidism/myxoedema
T86 [2002001128]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
0
11
79
767
Photocoagulation of retina
CKC12 [2001301394]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
5
79
773
Teeth/gum symptom/complaint
D19 [2002000318]
-3.5e-01
7.9e-01
—
—
—
8.8e-01
2.0e-02
cases:5.66%
controls:7.86%
cases:5.66%
controls:2.65%
—
—
—
—
—
—
cases:7.00%
controls:3.01%
cases:7.59%
controls:7.46%
6
83
100
973
6
28
100
1028
—
—
—
7
30
93
966
6
58
73
720
Periodontal treatment, very brief
SDA01 [2001310326]
-1.4e-01
-1.0e+50
—
—
—
—
—
cases:4.72%
controls:5.40%
cases:0.00%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
5
57
101
999
0
11
106
1045
—
—
—
—
—
Glucose [Moles/volume] in Venous blood
39480-9 [3038515]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
cases:0.00%
controls:0.90%
—
—
—
—
—
0
5
100
991
0
7
79
771
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
0
8
106
1048
—
—
—
—
—
Need for immunization against unspecified infectious disease
Z26.9 [45590712]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
0
6
106
1050
—
—
—
—
—
0
8
79
770
phenoxymethylpenicillin; oral
J01CE02 [21602842]
4.2e-01
—
—
—
—
—
5.9e-01
cases:18.87%
controls:13.26%
—
—
—
—
—
—
—
—
—
—
cases:17.72%
controls:10.67%
20
140
86
916
—
—
—
—
—
14
83
65
695
Vacuum extractor delivery
O81.4 [45582577]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
106
1050
—
—
—
—
—
—
Extensive health certificate
SPAT1284 [2001700385]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
—
mometasone, combinations
R01AD59 [947911]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
0
7
106
1049
—
—
—
0
5
100
991
—
olopatadine
R01AC08 [21605040]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
0
7
106
1049
—
—
—
0
5
100
991
—
fluvastatin; oral
C10AA04 [21601859]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
Concise certificate
WZA00 [2001310879]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
0
8
106
1048
—
—
—
—
0
5
100
991
—
Primary arthrosis of other joints
M19.0 [45601353]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
0
8
106
1048
—
—
—
—
—
Fever, unspecified
R50.9 [45582716]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
0
7
106
1049
—
—
—
—
—
Polyp of corpus uteri
N84.0 [45596887]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
0
5
100
991
—
glyceryl trinitrate; local oral, oral, sublingual, transdermal
C01DA02 [21600317]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
—
—
—
—
—
—
—
—
—
—
—
0
12
106
1044
—
—
—
—
—
Supraglottic ventilation device
WX702 [2001310818]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
—
Adhesive capsulitis of shoulder
M75.0 [45533931]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
—
Seborrhoeic keratosis
L82 [45548208]
2.8e-01
—
—
—
—
—
9.6e-02
cases:4.72%
controls:3.60%
—
—
—
—
—
—
—
—
—
—
cases:6.33%
controls:5.78%
5
38
101
1018
—
—
—
—
—
5
45
74
733
insulin aspart; parenteral
A10AD05 [21600733]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
cases:0.00%
controls:2.56%
cases:0.00%
controls:2.37%
—
—
—
—
cases:0.00%
controls:0.86%
cases:0.00%
controls:2.61%
—
—
0
27
106
1029
0
25
106
1031
—
—
0
9
105
1041
0
26
100
970
—
eletriptan; oral
N02CC06 [21604381]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
106
1049
—
—
—
—
—
—
Anesthesiology Critical Care Medicine
OMOP4821991 [45756751]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
0
11
79
767
Repair work or maintenance done on the aid
R5130 [2001310248]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
0
5
100
991
—
hydrocortisone and antiinfectives
S03CA04 [21605208]
—
—
—
—
—
—
7.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.33%
controls:3.08%
—
—
—
—
—
—
5
24
74
754
Ultrasound examination of pregnancy (at 12. week of gestaion or later) including basic examination of fetus
MA2AE [2001306829]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
0
6
106
1050
—
—
—
—
0
11
79
767
Migraine
G43 [45566873]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
0
7
106
1049
—
—
—
—
—
0
6
79
772
Body temperature
8310-5 [3020891]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.33%
controls:1.03%
—
—
—
—
—
—
5
8
74
770
Borrelia burgdorferi IgG Ab [Units/volume] in Serum
7817-0 [3016888]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
0
5
100
991
—
Body mass index
60621009 [4245997]
-7.6e-01
—
—
—
—
—
1.0e+50
cases:13.21%
controls:24.53%
—
—
—
—
—
—
—
—
—
—
cases:17.72%
controls:0.00%
14
259
92
797
—
—
—
—
—
14
0
65
778
Spinal stenosis
M48.0 [45557888]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
0
5
105
1045
—
—
Subcutaneous
ZX112 [2001311492]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
—
Smooth muscle Ab [Titer] in Serum
8095-2 [3007566]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
—
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
2.7e-01
—
—
—
—
—
-1.9e-01
cases:8.49%
controls:6.63%
—
—
—
—
—
—
—
—
—
—
cases:8.86%
controls:10.54%
9
70
97
986
—
—
—
—
—
7
82
72
696
Nutrition survey
SPAT1139 [2001700240]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
—
Bloodpressure measurement
XF600 [2001303376]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
106
1050
—
—
—
—
—
—
Anaemia vit B12/folate deficiency
B81 [2002000292]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
cases:0.00%
controls:1.54%
—
—
—
—
—
0
9
100
987
0
12
79
766
fluocinolone acetonide and antiinfectives
S02CA05 [21605177]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.14%
cases:0.00%
controls:0.57%
—
—
—
—
—
—
cases:0.00%
controls:0.70%
cases:0.00%
controls:0.90%
0
12
106
1044
0
6
106
1050
—
—
—
0
7
100
989
0
7
79
771
Joint ultrasound examination not elsewhere classified
NK4XE [2001308469]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
106
1041
—
—
—
—
—
—
Elbow X-ray examination without contrast
NC1AA [2001307421]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
6
79
772
naproxen; oral, rectal
M01AE02 [21603968]
4.5e-01
—
—
—
-1.0e+50
—
7.8e-01
cases:14.15%
controls:9.47%
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
cases:15.19%
controls:7.58%
15
100
91
956
—
—
—
0
7
105
1043
—
12
59
67
719
Moderate depressive episode without somatic syndrome
F32.10 [2000501980]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.33%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
0
14
106
1042
—
—
—
—
—
0
6
79
772
Lumbar spine X-ray examination without contrast
NA3AA [2001307026]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
0
6
106
1050
—
—
—
—
—
Oxygen saturation in Venous blood
2711-0 [3024928]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.29%
—
—
—
—
—
—
0
10
79
768
Coloscopy
UJF32 [2001305029]
6.7e-01
-1.0e+50
—
—
—
—
9.6e-01
cases:6.60%
controls:3.50%
cases:0.00%
controls:1.04%
—
—
—
—
—
—
—
—
cases:10.13%
controls:4.11%
7
37
99
1019
0
11
106
1045
—
—
—
—
8
32
71
746
Uroflowmetry
44856007 [4261340]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.29%
—
—
—
—
—
—
0
10
79
768
lamotrigine; oral
N03AX09 [21604431]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
cases:0.00%
controls:1.03%
0
5
106
1051
—
—
—
—
0
8
100
988
0
8
79
770
Moderate depressive episode
F32.1 [45552478]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
—
Presence of external hearing-aid
Z97.4 [45542504]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
0
7
100
989
—
Diabetes, insulin-treated
103 [2001600103]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
0
9
106
1047
—
—
—
0
8
100
988
—
Fear of respiratory disease other
R27 [2002000896]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
—
fluocortolone
D07AC05 [21602124]
1.7e+00
—
—
—
—
—
—
cases:4.72%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
5
9
101
1047
—
—
—
—
—
—
Person consulting for explanation of investigation findings
Z71.2 [45552100]
3.5e-01
—
—
—
—
-1.0e+50
5.8e-02
cases:6.60%
controls:4.73%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.31%
cases:7.59%
controls:7.20%
7
50
99
1006
—
—
—
—
0
23
100
973
6
56
73
722
timolol, combinations
S01ED51 [21603705]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
0
6
106
1050
—
—
—
—
Foot/toe symptom/complaint
L17 [2002000641]
4.9e-01
8.7e-01
—
—
—
—
3.2e-01
cases:8.49%
controls:5.40%
cases:7.55%
controls:3.31%
—
—
—
—
—
—
—
—
cases:10.13%
controls:7.58%
9
57
97
999
8
35
98
1021
—
—
—
—
8
59
71
719
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.52%
cases:0.00%
controls:1.04%
—
—
—
—
—
—
cases:0.00%
controls:1.51%
cases:0.00%
controls:2.06%
0
16
106
1040
0
11
106
1045
—
—
—
0
15
100
981
0
16
79
762
Essential (primary) hypertension
I10 [45591453]
1.8e-02
3.6e-01
-1.0e+50
—
—
1.5e-02
2.1e-01
cases:20.75%
controls:20.45%
cases:14.15%
controls:10.32%
cases:0.00%
controls:1.80%
—
—
—
—
cases:12.00%
controls:11.85%
cases:31.65%
controls:27.38%
22
216
84
840
15
109
91
947
0
19
106
1037
—
—
12
118
88
878
25
213
54
565
Functional dyspepsia
K30 [45591584]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
0
6
106
1050
—
—
—
—
—
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
1.7e-01
2.6e-01
—
—
—
-4.6e-03
6.6e-01
cases:27.36%
controls:24.15%
cases:14.15%
controls:11.27%
—
—
—
—
—
—
cases:13.00%
controls:13.05%
cases:39.24%
controls:24.94%
29
255
77
801
15
119
91
937
—
—
—
13
130
87
866
31
194
48
584
Cancer Ag 19-9 [Units/volume] in Serum or Plasma
24108-3 [3022914]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.14%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
0
12
106
1044
—
—
—
—
—
0
7
79
771
losartan and diuretics
C09DA01 [21601834]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
7
106
1049
—
0
6
105
1044
—
—
Tremor, unspecified
R25.1 [45539327]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
0
7
79
771
Counselling and guidance related to ageing
SPAT1304 [2001700405]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
106
1046
—
—
—
—
—
—
Iron deficiency anaemia
B80 [2002000291]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
0
5
106
1051
—
—
—
—
—
0
7
79
771
Apolipoprotein B [Mass/volume] in Serum or Plasma
1884-6 [3014791]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
0
5
106
1051
—
—
—
—
—
0
5
79
773
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
—
—
—
—
—
—
8.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.39%
controls:5.01%
—
—
—
—
—
—
9
39
70
739
chlorhexidine
S02AA09 [21605155]
1.2e+00
—
—
—
—
1.5e+00
—
cases:6.60%
controls:1.99%
—
—
—
—
—
—
—
—
cases:5.00%
controls:1.20%
—
—
7
21
99
1035
—
—
—
—
5
12
95
984
—
Malignant tumor of the upper outer quadrant of the mammary gland, other or undeterminated histology
C50.49 [2000501004]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
—
Celiac disease serology panel - Serum
94494-2 [36660697]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
—
0
9
100
987
—
Zoster [herpes zoster]
B02 [45552205]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
8
79
770
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: former
SMOKING-2-2-4 [2002330109]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
106
1045
—
—
—
—
—
—
Multiple adjuvant cytostatic therapy
WB113 [2001310629]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
106
1045
—
—
—
—
—
—
Emergency treatment
SGA01 [2001310379]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
0
8
106
1048
—
—
—
—
—
Infiltration anesthesia
WX110 [2001310767]
-2.5e-01
-1.7e-01
-1.0e+50
—
—
-9.8e-02
5.0e-01
cases:19.81%
controls:24.15%
cases:7.55%
controls:8.81%
cases:0.00%
controls:1.61%
—
—
—
—
cases:9.00%
controls:9.84%
cases:32.91%
controls:22.88%
21
255
85
801
8
93
98
963
0
17
106
1039
—
—
9
98
91
898
26
178
53
600
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
3.8e-01
2.9e-01
—
—
—
2.0e-01
1.5e-01
cases:22.64%
controls:16.67%
cases:6.60%
controls:5.02%
—
—
—
—
—
—
cases:10.00%
controls:8.33%
cases:21.52%
controls:19.02%
24
176
82
880
7
53
99
1003
—
—
—
10
83
90
913
17
148
62
630
Acute sinusitis
J01 [45548098]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
106
1046
—
—
—
—
—
—
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
-1.0e-01
—
—
—
—
—
—
cases:4.72%
controls:5.21%
—
—
—
—
—
—
—
—
—
—
—
—
5
55
101
1001
—
—
—
—
—
—
Laparoscopic appendectomy
JEA01 [2001304803]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
—
Monitoring the use of the aid
R5140 [2001310249]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
0
6
106
1050
—
—
—
—
—
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
1.6e-02
3.6e-01
5.8e-01
—
1.7e-01
-1.3e-01
6.4e-01
cases:44.34%
controls:43.94%
cases:38.68%
controls:30.59%
cases:10.38%
controls:6.06%
—
—
cases:7.62%
controls:6.48%
cases:30.00%
controls:32.83%
cases:70.89%
controls:56.30%
47
464
59
592
41
323
65
733
11
64
95
992
—
8
68
97
982
30
327
70
669
56
438
23
340
Hyaline casts [#/volume] in Urine by Automated count
51484-4 [3030981]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
cases:0.00%
controls:1.10%
—
—
—
0
6
106
1050
—
—
—
0
11
100
985
—
Emergency Room Visit
ER [9203]
5.0e-01
6.9e-01
-1.0e+50
—
—
3.0e-01
1.5e-01
cases:45.28%
controls:33.43%
cases:16.98%
controls:9.28%
cases:0.00%
controls:1.52%
—
—
—
—
cases:15.00%
controls:11.55%
cases:30.38%
controls:27.38%
48
353
58
703
18
98
88
958
0
16
106
1040
—
—
15
115
85
881
24
213
55
565
Doppler ultrasound examination of heart
FM1DE [2001303299]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
cases:0.00%
controls:1.80%
—
—
—
—
—
0
5
100
991
0
14
79
764
MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal
72872-5 [43534045]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
0
7
106
1049
—
—
—
—
—
hydrochlorothiazide and potassium-sparing agents
C03EA01 [21601543]
8.2e-01
—
—
—
-1.0e+50
—
9.4e-01
cases:6.60%
controls:3.03%
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
cases:6.33%
controls:2.57%
7
32
99
1024
—
—
—
0
7
105
1043
—
5
20
74
758
Diabetes insulin dependent
T89 [2002001130]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.85%
cases:0.00%
controls:1.04%
—
—
—
—
—
—
cases:0.00%
controls:0.80%
cases:0.00%
controls:1.41%
0
9
106
1047
0
11
106
1045
—
—
—
0
8
100
988
0
11
79
767
hydroxyethylpromethazine, combinations
R06AD55 [21603490]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.52%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
0
16
106
1040
—
—
—
—
—
0
5
79
773
Benign neoplasm: Caecum
D12.0 [45586086]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
5
79
773
Corneal ulcer
H16.0 [45557339]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
106
1048
—
—
—
—
—
—
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
-2.2e-01
6.4e-01
-1.0e+50
—
-1.0e+50
4.6e-01
1.2e-01
cases:10.38%
controls:12.59%
cases:9.43%
controls:5.21%
cases:0.00%
controls:0.47%
—
—
cases:0.00%
controls:0.67%
cases:10.00%
controls:6.53%
cases:17.72%
controls:16.07%
11
133
95
923
10
55
96
1001
0
5
106
1051
—
0
7
105
1043
10
65
90
931
14
125
65
653
Bacteria [Presence] in Urine
87829-8 [36304419]
1.7e-01
—
—
—
—
4.6e-01
3.1e-01
cases:8.49%
controls:7.29%
—
—
—
—
—
—
—
—
cases:5.00%
controls:3.21%
cases:11.39%
controls:8.61%
9
77
97
979
—
—
—
—
5
32
95
964
9
67
70
711
Primary partial prosthetic replacement of hip joint using cement, other or unspecified
NFB20 [2001307920]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
—
Impingement syndrome of shoulder
M75.4 [45553266]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
0
9
106
1047
—
—
—
—
—
0
7
79
771
ibuprofen
R02AX02 [1588667]
2.1e-01
1.2e-01
—
—
—
3.0e-01
4.4e-01
cases:42.45%
controls:37.50%
cases:17.92%
controls:16.19%
—
—
—
—
—
—
cases:20.00%
controls:15.66%
cases:46.84%
controls:36.12%
45
396
61
660
19
171
87
885
—
—
—
20
156
80
840
37
281
42
497
dexchlorpheniramine, combinations
R06AB52 [21603467]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.33%
controls:1.16%
—
—
—
—
—
—
5
9
74
769
Postmenopausal atrophic vaginitis
N95.2 [45582430]
1.1e+00
—
—
—
—
—
1.9e+00
cases:4.72%
controls:1.61%
—
—
—
—
—
—
—
—
—
—
cases:6.33%
controls:1.03%
5
17
101
1039
—
—
—
—
—
5
8
74
770
Nutritional therapy
R4190 [2001310243]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.66%
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
0
7
106
1049
0
5
106
1051
—
—
—
—
—
Guidance related to psychoactive substances / risk behaviour
SPAT1309 [2001700410]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
6
79
772
insulin (beef); parenteral
A10AD02 [21600730]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
0
6
105
1044
—
—
Opening and preparing the root canals, extremely complicated And time consuming
SGA05 [2001310383]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
5
79
773
Very demanding periodontal treatment
SDA05 [2001310330]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.16%
—
0
7
106
1049
—
—
—
—
0
9
79
769
Varicella zoster virus IgM Ab [Presence] in Serum by Immunoassay
29662-4 [3012220]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
106
1047
—
—
—
—
—
—
Herpes simplex virus 1+2 DNA [Presence] in Specimen by NAA with probe detection
20444-6 [3028369]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
5
79
773
ispaghula (psylla seeds); oral
A06AC01 [21600555]
5.2e-01
2.3e-01
—
—
-1.0e+50
1.8e-01
6.1e-01
cases:8.49%
controls:5.21%
cases:4.72%
controls:3.79%
—
—
—
—
cases:0.00%
controls:0.67%
cases:5.00%
controls:4.22%
cases:10.13%
controls:5.78%
9
55
97
1001
5
40
101
1016
—
—
0
7
105
1043
5
42
95
954
8
45
71
733
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
cases:0.00%
controls:1.80%
—
—
—
—
—
0
7
100
989
0
14
79
764
Gas panel - Venous blood
24339-4 [3000991]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
0
7
106
1049
—
—
—
0
6
100
990
—
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
6.0e-03
—
—
—
—
4.6e-01
5.5e-01
cases:10.38%
controls:10.32%
—
—
—
—
—
—
—
—
cases:8.00%
controls:5.22%
cases:17.72%
controls:11.05%
11
109
95
947
—
—
—
—
8
52
92
944
14
86
65
692
Missed abortion
O02.1 [45567878]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
106
1050
—
—
—
—
—
—
magnesium hydroxide; oral
A02AA04 [21600052]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
6
79
772
Postpartum check-up
SPAT1380 [2001700480]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
6
79
772
Intraoral radiographic dental examination
EB1AA [2001301903]
-1.0e-01
—
—
—
—
4.6e-01
1.6e-01
cases:16.04%
controls:17.42%
—
—
—
—
—
—
—
—
cases:8.00%
controls:5.22%
cases:20.25%
controls:17.74%
17
184
89
872
—
—
—
—
8
52
92
944
16
138
63
640
fluticasone furoate
R03BA09 [45893496]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
0
5
106
1051
—
0
5
105
1045
—
—
donepezil; oral
N06DA02 [21604795]
—
—
—
—
-1.0e+50
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
cases:0.00%
controls:0.70%
cases:0.00%
controls:1.03%
—
—
—
—
0
6
105
1044
0
7
100
989
0
8
79
770
antibiotics in combination with other drugs
S01AA20 [21603571]
-1.7e-01
1.2e+00
-1.0e+50
—
—
7.9e-01
1.9e-01
cases:6.60%
controls:7.77%
cases:6.60%
controls:2.18%
cases:0.00%
controls:0.47%
—
—
—
—
cases:6.00%
controls:2.81%
cases:11.39%
controls:9.64%
7
82
99
974
7
23
99
1033
0
5
106
1051
—
—
6
28
94
968
9
75
70
703
Urine symptom/complaint other
U07 [2002001142]
1.2e+00
—
—
—
—
—
—
cases:4.72%
controls:1.52%
—
—
—
—
—
—
—
—
—
—
—
—
5
16
101
1040
—
—
—
—
—
—
triamcinolone and antiseptics
D07BB03 [21602150]
1.4e+00
—
—
—
—
1.5e+00
—
cases:7.55%
controls:1.99%
—
—
—
—
—
—
—
—
cases:5.00%
controls:1.20%
—
—
8
21
98
1035
—
—
—
—
5
12
95
984
—
melatonin; oral
N05CH01 [21604659]
-4.0e-03
—
-1.0e+50
—
-1.0e+50
—
—
cases:4.72%
controls:4.73%
—
—
cases:0.00%
controls:0.57%
—
—
cases:0.00%
controls:0.67%
—
—
—
—
5
50
101
1006
—
0
6
106
1050
—
0
7
105
1043
—
—
Cholesterol non HDL [Moles/volume] in Serum or Plasma
70204-3 [42868678]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
—
0
9
100
987
—
Contusion of thorax
S20.2 [45597402]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
106
1050
—
—
—
—
—
—
phenylpropanolamine, combinations; oral
R01BA51 [21603212]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.61%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
0
17
106
1039
—
—
—
—
—
0
5
79
773
Cytomegalovirus IgG Ab [Titer] in Serum or Plasma
22246-3 [3017918]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
—
linagliptin; oral
A10BH05 [40251691]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
0
6
106
1050
—
—
—
0
6
100
990
—
bromfenac
S01BC11 [21603649]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
5
79
773
Plastic And Reconstructive Surgery
24 [38004467]
—
—
—
—
—
—
5.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.59%
controls:4.76%
—
—
—
—
—
—
6
37
73
741
Spontaneous vertex delivery
O80.0 [45577661]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
0
5
106
1051
—
—
—
0
10
100
986
—
mesalazine; oral, rectal
A07EC02 [21600664]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.14%
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
0
12
106
1044
0
7
106
1049
—
—
—
—
0
7
79
771
Periapical abscess without sinus
K04.7 [45586692]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
5
79
773
Teeth/gum disease
D82 [2002000380]
2.2e-01
—
—
—
—
1.8e-01
6.3e-01
cases:11.32%
controls:9.28%
—
—
—
—
—
—
—
—
cases:5.00%
controls:4.22%
cases:17.72%
controls:10.28%
12
98
94
958
—
—
—
—
5
42
95
954
14
80
65
698
Disturbance of activity and attention
F90.0 [45542870]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
0
5
106
1051
—
—
—
—
0
5
100
991
—
Curettage of uterus after delivery or abortion
MBA03 [2001306930]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
—
Examination of eyes and vision
Z01.0 [45566391]
7.1e-01
—
—
—
—
—
5.2e-01
cases:4.72%
controls:2.37%
—
—
—
—
—
—
—
—
—
—
cases:6.33%
controls:3.86%
5
25
101
1031
—
—
—
—
—
5
30
74
748
Spinalanesthesia
WX320 [2001310799]
—
-1.0e+50
—
—
—
—
3.6e-01
—
—
cases:0.00%
controls:1.42%
—
—
—
—
—
—
—
—
cases:6.33%
controls:4.50%
—
0
15
106
1041
—
—
—
—
5
35
74
743
folic acid; oral, parenteral
B03BB01 [21601129]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
0
6
106
1050
—
—
—
—
Swollen ankles/oedema
K07 [2002000550]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
106
1050
—
—
—
—
—
—
Differential panel, method unspecified - Blood
69738-3 [42870588]
-1.3e-01
3.1e-01
8.9e-01
—
1.0e+00
6.8e-01
4.6e-01
cases:9.43%
controls:10.61%
cases:8.49%
controls:6.34%
cases:4.72%
controls:1.99%
—
—
cases:4.76%
controls:1.81%
cases:13.00%
controls:7.03%
cases:16.46%
controls:11.05%
10
112
96
944
9
67
97
989
5
21
101
1035
—
5
19
100
1031
13
70
87
926
13
86
66
692
colestyramine; oral
C10AC01 [21601876]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
—
Complicated extraction of tooth
EBA05 [2001301924]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
0
10
106
1046
—
—
—
—
—
Mastodynia
N64.4 [45539060]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
106
1050
—
—
—
—
—
—
Retinol [Moles/volume] in Serum or Plasma
14905-4 [3013005]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
—
Haptoglobin [Mass/volume] in Serum or Plasma
4542-7 [3012336]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
0
5
106
1051
—
—
—
—
0
5
79
773
Personal history of diseases of the digestive system
Z87.1 [45542474]
2.0e-01
—
—
—
-1.0e+50
—
9.0e-02
cases:16.98%
controls:14.39%
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
cases:12.66%
controls:11.70%
18
152
88
904
—
—
—
0
5
105
1045
—
10
91
69
687
nimesulide; oral
M01AX17 [21604007]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
6
79
772
sitagliptin; oral
A10BH01 [21600784]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:1.80%
cases:0.00%
controls:0.57%
—
—
cases:0.00%
controls:1.05%
cases:0.00%
controls:2.01%
cases:0.00%
controls:2.96%
—
0
19
106
1037
0
6
106
1050
—
0
11
105
1039
0
20
100
976
0
23
79
755
Abnormal findings on diagnostic imaging of lung
R91 [45548995]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
8
79
770
Abdominal CT examination
JN3AD [2001305554]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
0
8
100
988
—
meloxicam; oral, parenteral, rectal
M01AC06 [21603965]
2.5e-01
—
-1.0e+50
—
—
—
1.4e-01
cases:6.60%
controls:5.21%
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
cases:6.33%
controls:5.53%
7
55
99
1001
—
0
6
106
1050
—
—
—
5
43
74
735
Attention to surgical dressings and sutures
Z48.0 [45609943]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.76%
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
0
8
106
1048
0
5
106
1051
—
—
—
—
—
Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep
18500-9 [3018006]
6.9e-01
—
—
—
—
—
5.0e-01
cases:12.26%
controls:6.53%
—
—
—
—
—
—
—
—
—
—
cases:7.59%
controls:4.76%
13
69
93
987
—
—
—
—
—
6
37
73
741
More than three and less than five hours
ZXE20 [2001311408]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.18%
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
0
23
106
1033
0
5
106
1051
—
—
—
—
—
pegfilgrastim; parenteral
L03AA13 [21603856]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
0
7
106
1049
—
—
—
—
—
0
5
79
773
Helicobacter pylori Ag [Presence] in Stool
31843-6 [3013139]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.54%
—
0
7
106
1049
—
—
—
—
0
12
79
766
Pure hypercholesterolaemia
E78.01 [2000501514]
3.4e-01
—
—
—
—
—
5.8e-02
cases:4.72%
controls:3.41%
—
—
—
—
—
—
—
—
—
—
cases:7.59%
controls:7.20%
5
36
101
1020
—
—
—
—
—
6
56
73
722
Psoriasis vulgaris
L40.0 [45543370]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
6
79
772
dexbrompheniramine, combinations
R06AB56 [21603469]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.33%
controls:1.16%
—
—
—
—
—
—
5
9
74
769
C reactive protein [Mass/volume] in Serum or Plasma by High sensitivity method
30522-7 [3010156]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
0
8
106
1048
—
—
—
—
—
0
6
79
772
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
-3.6e-02
1.9e-01
5.5e-01
—
-1.6e-01
3.9e-01
8.7e-02
cases:32.08%
controls:32.86%
cases:29.25%
controls:25.57%
cases:9.43%
controls:5.68%
—
—
cases:5.71%
controls:6.67%
cases:35.00%
controls:26.71%
cases:44.30%
controls:42.16%
34
347
72
709
31
270
75
786
10
60
96
996
—
6
70
99
980
35
266
65
730
35
328
44
450
Endoscopic polypectomy in colon
JFA15 [2001304850]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.16%
0
5
106
1051
—
—
—
—
—
0
9
79
769
Submucous leiomyoma of uterus
D25.0 [45542691]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
—
General Practice Dentistry
1223G0001X [38003675]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
106
1047
—
—
—
—
—
—
Obesity
T82 [2002001125]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
106
1050
—
—
—
—
—
—
Extensive CT examination of arteria pulmonalis
FB1BD [2001302407]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
106
1048
—
—
—
—
—
—
fusidic acid; ointment
D06AX01 [21602062]
7.3e-01
—
—
—
—
—
1.1e+00
cases:8.49%
controls:4.26%
—
—
—
—
—
—
—
—
—
—
cases:8.86%
controls:3.08%
9
45
97
1011
—
—
—
—
—
7
24
72
754
Excision of skin or mucous membrane lesion
SPAT1141 [2001700242]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
106
1047
—
—
—
—
—
—
ECG with 12 standard connections
XF400 [2001303368]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
cases:0.00%
controls:0.90%
cases:0.00%
controls:1.03%
—
0
6
106
1050
—
—
—
0
9
100
987
0
8
79
770
Influenza virus A+B Ag [Presence] in Specimen
24015-0 [3024891]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
106
1049
—
—
—
—
—
—
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
-2.6e-01
4.6e-01
—
—
—
—
3.8e-01
cases:5.66%
controls:7.20%
cases:4.72%
controls:3.03%
—
—
—
—
—
—
—
—
cases:12.66%
controls:9.00%
6
76
100
980
5
32
101
1024
—
—
—
—
10
70
69
708
methylprednisolone; oral, parenteral
H02AB04 [21602732]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
0
6
100
990
—
Kappa light chains/Lambda light chains [Mass Ratio] in Serum
15189-4 [3007778]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
0
7
106
1049
—
—
—
—
—
0
7
79
771
ranitidine bismuth citrate; oral
A02BA07 [21600088]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
0
9
106
1047
—
—
—
0
9
100
987
—
Breast cancer
115 [2001600115]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:2.46%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
0
26
106
1030
—
—
—
—
—
0
5
79
773
chlorhexidine
D09AA12 [21602275]
1.2e+00
—
—
—
—
1.5e+00
—
cases:6.60%
controls:1.99%
—
—
—
—
—
—
—
—
cases:5.00%
controls:1.20%
—
—
7
21
99
1035
—
—
—
—
5
12
95
984
—
Unspecified lump in breast
N63 [45601743]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.16%
0
7
106
1049
—
—
—
—
—
0
9
79
769
Shoulder syndrome
L92 [2002000711]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
106
1049
—
—
—
—
—
—
celecoxib
L01XX33 [21603805]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.93%
—
—
—
—
—
—
0
15
79
763
covid-19, RNA-based vaccine
J07BN01 [954934]
-1.2e-01
2.9e-01
—
—
—
-1.6e-01
-9.6e-02
cases:17.92%
controls:19.70%
cases:13.21%
controls:10.23%
—
—
—
—
—
—
cases:10.00%
controls:11.55%
cases:34.18%
controls:36.38%
19
208
87
848
14
108
92
948
—
—
—
10
115
90
881
27
283
52
495
Arthrosis, unspecified
M19.9 [45543488]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
cases:0.00%
controls:1.54%
—
—
—
—
—
0
5
100
991
0
12
79
766
folic acid
V04CX02 [715877]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
0
6
106
1050
—
—
—
—
Chronic glaucoma with open ventricular angle
H40.13 [2000502335]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
8
79
770
Familial hypercholesterolaemia
E78.00 [2000501513]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
—
etoricoxib; oral
M01AH05 [21603996]
-1.2e-01
-4.9e-01
—
—
—
1.8e-01
2.9e-01
cases:16.04%
controls:17.71%
cases:4.72%
controls:7.48%
—
—
—
—
—
—
cases:7.00%
controls:5.92%
cases:22.78%
controls:18.12%
17
187
89
869
5
79
101
977
—
—
—
7
59
93
937
18
141
61
637
ebastine; oral
R06AX22 [21603521]
6.5e-01
—
—
—
—
1.2e+00
1.4e+00
cases:5.66%
controls:3.03%
—
—
—
—
—
—
—
—
cases:5.00%
controls:1.51%
cases:6.33%
controls:1.67%
6
32
100
1024
—
—
—
—
5
15
95
981
5
13
74
765
Dental calculus supragingival
K03.64 [2000502689]
7.5e-02
—
—
—
—
—
—
cases:6.60%
controls:6.16%
—
—
—
—
—
—
—
—
—
—
—
—
7
65
99
991
—
—
—
—
—
—
mycophenolic acid; oral, parenteral
L04AA06 [21603896]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
0
5
106
1051
—
—
—
—
0
5
100
991
—
Intravenous administration of medicine
SPAT1255 [2001700356]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
106
1048
—
—
—
—
—
—
Cervicobrachial syndrome
M53.1 [45567577]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
0
5
106
1051
—
—
—
—
—
Albumin/Creatinine [Ratio] in Urine
32294-1 [3020682]
-2.6e-01
-2.8e-01
—
—
—
—
3.3e-01
cases:7.55%
controls:9.56%
cases:4.72%
controls:6.16%
—
—
—
—
—
—
—
—
cases:18.99%
controls:14.40%
8
101
98
955
5
65
101
991
—
—
—
—
15
112
64
666
Naevus/mole
S82 [2002001046]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
0
7
106
1049
—
—
—
0
8
100
988
—
Type 2 diabetes mellitus, with unspecified complications
E11.8 [45561951]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.95%
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
0
10
106
1046
0
6
106
1050
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
36
48
10.84
27.31
1.4
1.1
—
—
—
0
0
23
45
6.25
11.88
3.4
1.8
19.06
6.63
iu/ml
0.78
13
12
43
160
3.84
9.98
1.4
1.4
386.67
589.79
titre
0.71
12
47
82
534
3.37
6.71
7.1
5.8
1.93
2.01
e9/l
0.17
75
469
82
538
3.32
6.54
7.1
6.0
0.19
0.17
e9/l
0.34
75
468
80
526
3.12
6.19
7.3
5.8
0.05
0.04
e9/l
1.13
72
443
79
522
3.02
5.94
7.4
5.8
0.54
0.54
e9/l
0.03
71
442
11
15
8.04
5.29
4.1
2.1
3.75
4.50
e9/l
0.38
11
15
27
111
2.92
4.97
1.4
1.5
—
—
—
0
0
13
32
4.48
4.07
3.2
1.5
0.21
0.22
g/l
0.08
13
32
96
783
3.40
3.64
5.7
4.9
14.49
15.00
pmol/l
1.51
84
704
11
26
4.59
3.62
4.0
2.3
52.45
62.07
%
1.87
11
26
53
340
2.12
3.52
5.6
5.1
—
—
—
0
0
40
233
2.15
3.38
7.9
5.9
—
—
—
0
0
17
69
2.74
3.15
3.1
3.9
—
—
—
0
0
92
752
2.69
3.12
7.9
8.1
72.45
79.05
u/l
1.37
87
703
76
577
2.12
3.03
8.9
10.2
3.64
3.83
e9/l
0.44
69
500
8
17
5.00
2.98
1.1
1.1
—
—
—
0
0
59
413
1.97
2.92
2.7
2.0
—
—
—
0
0
39
243
1.96
2.66
1.6
1.8
0.60
1.21
mg/l
1.53
33
199
12
45
2.88
2.55
1.1
1.2
—
—
—
0
0
19
93
2.27
2.39
1.5
1.5
—
—
—
0
0
59
439
1.78
2.19
5.3
3.9
6.39
6.31
ph
0.19
35
222
39
257
1.82
2.18
1.6
1.3
0.47
2.17
u/ml
0.92
12
60
5
12
4.31
1.84
1.8
1.1
—
—
—
0
0
43
305
1.69
1.81
2.6
2.5
59.37
53.94
u/l
0.46
38
276
60
465
1.67
1.80
12.2
11.7
0.00
0.01
e9/l
0.52
54
366
49
362
1.66
1.76
2.4
3.1
2.37
2.36
mmol/l
0.22
42
333
5
14
3.69
1.63
1.0
1.1
—
2.65
—
0
7
5
14
3.69
1.63
1.0
1.1
—
1.52
—
0
5
14
71
2.12
1.63
5.7
4.0
—
—
—
0
0
9
38
2.49
1.50
2.6
1.6
—
—
—
0
0
16
89
1.94
1.47
1.5
1.7
—
—
—
0
0
53
417
1.54
1.37
6.6
4.0
0.00
0.01
estimate
0.49
13
86
5
17
3.03
1.37
1.6
1.2
—
—
nmol/l
—
0
0
9
43
2.19
1.34
8.2
4.0
37.01
36.98
°c
—
9
43
67
557
1.55
1.34
6.5
4.2
0.00
0.00
estimate
-0.00
14
105
67
560
1.53
1.28
6.5
4.3
0.00
14.76
estimate
0.50
17
110
46
355
1.52
1.28
3.8
3.3
—
—
—
0
0
67
566
1.50
1.17
6.4
4.3
0.00
0.00
estimate
-0.00
17
106
38
286
1.51
1.17
3.8
3.4
0.39
0.47
e6/l
0.10
28
190
20
129
1.68
1.16
7.7
6.5
106.00
104.16
mmol/l
1.99
20
129
32
235
1.52
1.10
1.4
1.5
2.63
2.46
g/l
0.18
23
136
42
328
1.46
1.07
3.9
3.5
12.69
23.45
e6/l
1.17
32
233
98
918
1.89
1.02
7.3
5.9
1.83
1.89
mu/l
0.21
88
839
38
294
1.46
1.01
9.0
4.3
0.00
0.00
estimate
-0.00
13
102
10
54
1.94
1.00
3.9
2.3
—
—
—
0
0
29
214
1.49
0.97
1.2
1.4
7.61
9.64
u/ml
0.14
14
85
99
932
1.94
0.96
5.9
5.3
5.71
5.85
mmol/l
0.88
94
860
20
136
1.58
0.95
2.8
2.0
—
—
—
0
0
28
208
1.47
0.90
1.9
1.8
457.18
492.10
pmol/l
0.18
22
172
100
949
1.95
0.89
6.8
6.0
2.79
2.76
mmol/l
0.12
94
873
14
91
1.62
0.80
1.4
1.6
—
—
—
0
0
12
75
1.68
0.79
1.8
2.4
0.08
1.42
e6/l
0.57
12
69
52
441
1.35
0.77
4.5
4.2
35.41
36.00
g/l
0.29
45
418
9
54
1.73
0.77
1.7
2.4
0.58
0.63
%
—
9
54
9
55
1.69
0.76
1.7
2.4
0.78
1.30
%
—
9
55
9
57
1.63
0.73
2.0
2.6
130.89
128.44
g/l
—
9
57
99
942
1.77
0.73
6.1
5.2
4.81
4.80
mmol/l
0.07
94
872
17
120
1.50
0.70
1.5
1.2
—
—
—
0
0
7
42
1.71
0.70
2.1
2.4
24.91
24.76
mmol/l
—
7
42
30
239
1.36
0.65
1.4
1.4
17.27
34.76
iu/ml
—
8
79
58
510
1.30
0.63
7.5
6.5
1.21
1.22
mmol/l
0.85
48
433
44
375
1.30
0.60
5.0
4.5
77.65
69.33
e6/l
0.07
32
238
0
22
0.00
0.60
0.0
1.0
—
3.13
—
0
15
0
23
0.00
0.59
0.0
1.1
—
73.53
—
0
17
53
465
1.28
0.57
6.9
5.6
1.21
1.22
mmol/l
0.51
47
420
95
903
1.50
0.56
8.1
6.5
37.88
38.83
mmol/mol
0.77
84
843
39
330
1.29
0.56
3.7
6.7
—
—
—
0
0
30
248
1.29
0.51
7.8
4.2
1.02
1.02
kg/l
0.10
14
155
23
283
0.76
0.50
1.5
1.4
—
—
—
0
0
98
944
1.50
0.49
19.8
15.3
20.82
19.94
mg/l
0.11
80
754
14
185
0.72
0.48
2.1
1.7
—
—
—
0
0
93
886
1.40
0.48
5.2
4.2
1.25
1.24
mmol/l
0.10
86
810
51
453
1.24
0.47
2.0
2.0
1.25
1.31
mmol/l
0.28
44
378
37
317
1.26
0.47
2.8
2.3
—
—
—
0
0
51
458
1.22
0.41
2.2
2.1
101.08
99.97
pmol/l
0.06
20
221
0
17
0.00
0.41
0.0
1.4
—
—
—
0
0
0
17
0.00
0.41
0.0
1.0
—
—
—
0
0
5
34
1.49
0.41
1.0
1.2
—
—
—
0
0
97
935
1.44
0.37
5.9
5.1
1.53
1.58
mmol/l
0.57
92
858
6
41
1.49
0.37
1.0
1.2
—
—
—
0
0
21
173
1.27
0.36
1.8
1.7
1408.83
1157.76
nmol/l
0.45
12
122
11
82
1.38
0.35
9.0
7.2
—
—
—
0
0
15
120
1.29
0.32
1.5
1.3
—
—
—
0
0
28
243
1.21
0.31
3.4
4.2
—
—
—
0
0
8
63
1.29
0.28
16.3
8.0
0.74
0.63
%
—
8
63
8
64
1.27
0.28
16.3
7.9
1.41
1.47
%
—
8
64
5
73
0.67
0.27
1.2
1.4
—
—
—
0
0
19
161
1.22
0.26
2.8
3.2
8.64
4.66
e6/l
0.46
11
68
18
153
1.21
0.24
1.3
1.2
—
—
—
0
0
5
37
1.37
0.24
3.2
1.6
—
—
—
0
0
33
299
1.15
0.22
1.9
1.7
27.19
22.49
nmol/l
0.63
26
245
0
11
0.00
0.21
0.0
2.6
—
48.83
—
0
6
0
10
0.00
0.21
0.0
2.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
2.26
—
0
10
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
37
339
1.14
0.21
3.9
3.9
7.39
7.40
ph
0.43
22
236
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
2.0
—
—
—
0
0
8
67
1.21
0.17
1.6
2.9
89.13
87.93
ng/l
—
8
61
8
71
1.14
0.16
1.1
1.8
0.88
1.53
g/l
—
8
66
13
114
1.16
0.12
1.3
1.4
—
—
—
0
0
40
379
1.09
0.12
5.9
3.8
22.99
22.72
ng/l
0.01
26
252
33
310
1.09
0.11
4.4
3.6
0.00
0.00
estimate
-0.00
14
82
33
347
0.93
0.09
3.6
2.9
6.36
7.00
mmol/l
0.46
27
286
48
463
1.07
0.08
3.4
2.8
—
—
estimate
—
0
0
7
68
1.03
0.08
1.1
1.4
—
—
—
0
0
98
969
1.15
0.07
18.0
13.2
—
—
—
0
0
9
101
0.88
0.06
1.6
1.3
—
—
—
0
0
10
90
1.12
0.05
1.2
1.1
—
—
—
0
0
37
358
1.05
0.05
4.1
3.1
—
—
—
0
0
14
150
0.92
0.04
1.4
1.7
30.70
29.41
s
0.29
14
145
10
91
1.11
0.04
1.9
2.3
9.88
9.89
g/l
—
10
86
11
116
0.94
0.01
12.4
7.3
7.44
7.42
ph
—
6
72
26
254
1.03
0.00
2.5
2.7
345.71
321.33
umol/l
0.56
21
220
33
332
0.99
0.00
3.7
3.1
8.22
37.24
mg/l
2.53
20
193
43
435
0.98
0.00
11.8
11.1
1.21
1.17
inr
0.17
37
351
33
334
0.98
0.00
4.4
3.6
2.15
7.81
mg/mmol
1.71
19
186
16
159
1.01
0.00
1.3
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
396.71
—
0
7
0
7
0.00
0.00
0.0
1.4
—
61.29
—
0
7
0
8
0.00
0.00
0.0
1.5
—
0.44
—
0
8
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
138.81
—
0
7
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
2.5
—
2121.25
—
0
8
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.8
—
4.00
—
0
5
0
5
0.00
-0.00
0.0
2.4
—
50.60
—
0
5
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
7.17
—
0
9
0
5
0.00
-0.00
0.0
1.0
—
1.67
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
8
85
0.94
-0.00
1.5
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint L12_HAIRLOSS_SCARNAS and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have L12_HAIRLOSS_SCARNAS.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

↥

Index endpoint: L12_HAIRLOSS_SCARNAS – Other and unspecified cicatricial alopecia

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data